GLP-1 drugs vs. nutrition counseling for Psoriatic Arthritis with obesity and diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a pragmatic randomized controlled trial in adults with psoriatic arthritis who also have obesity and diabetes. Participants will be randomized to receive a GLP-1 agonist or structured nutrition counseling, aiming to improve disease activity and overall health. The study focuses on real-world applicability, with up to four in-person visits over 24 weeks and collection of both clinical and patient-reported outcomes. Eligibility requires CASPAR-confirmed PsA, BMI ≥30, inadequate disease control, and FDA-appropriate GLP-1 eligibility. Primary goals include disease outcomes and patient-reported measures under the two treatment approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients (age 18 and older) who present to rheumatology clinic
* Participants must be able to read, understand, and provide documented informed consent as approved by the Institutional Review Board (IRB).
* Meet the Classification of Psoriatic Arthritis (CASPAR) criteria for PsA
* Participants must have a Body Mass Index (BMI) of 30kg/m\^2
* Participants must be treated for PsA in accordance with guidelines
* Have not achieved MDA in PsA patients
* Have a minimum TJC \> 1 and SJC \> at baseline
* Eligible for GLP-1 agonist treatment in accordance with Food Drug Administration (FDA) labeling as determined by the investigator.

Exclusion Criteria:

* Any prior use of GLP-1 agonists
* Inability to provide informed consent
* Current participation in another PsA study
* Treatment initiation by GLP-1 agonists contraindicated by FDA
* Patients with hemoglobin A1c (HbA1c) \> 10 at baseline

Where it's running

• Medical College of Wisconsin/Froedtert Hosptial
  Milwaukee, Wisconsin, United States Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Carotid ultrasound to guide prevention of heart disease in inflammatory rheumatic diseases

  In people with inflammatory rheumatic diseases like RA, PsA, AxSpA, or SLE who are at modest cardiovascular risk, a carotid ultrasound test is used to see if they should start stronger lipid-lowering therapy to prevent heart problems.

  Recruiting at 7 sites Phase 4 Instituto de Investigación Marqués de Valdecilla · Alicante, Alicante and 16 other locations · NCT07611747

• Oxidative stress in autoimmune joint diseases

  Researchers will see if oxidative stress and antioxidant markers differ in adults with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.

  Recruiting University of Thessaly · Larissa, Thessaly · NCT07536529

• Preventing early joint damage in people with recent-onset psoriatic arthritis

  This trial tests whether a TNF blocker (an adalimumab biosimilar) works better than injected methotrexate at preventing early joint damage in adults who recently developed psoriatic arthritis.

  Recruiting Phase 4 Chinese University of Hong Kong · Hong Kong · NCT07486843

• Self-management app to help people with inflammatory arthritis stay safe

  A smartphone app from the French Rheumatology Society is being tested to help adults with rheumatoid arthritis or spondyloarthritis manage their treatments and safety while starting a new DMARD.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07460739

• S-4321 in adults with autoimmune or immune-mediated diseases

  This study tests S-4321 in adults with autoimmune conditions to see if it is safe and tolerable and to gather early data on how the drug behaves in the body and its initial effects on disease markers.

  Recruiting at 2 sites Phase 1 Seismic Therapeutic AU Pty Ltd · Charlestown, New South Wales and 1 other locations · NCT07455578

• Combining the biologic ixekizumab with the weight-loss drug tirzepatide for people with psoriatic arthritis and overweight/obesity

  This trial will test whether ixekizumab, tirzepatide (a weight-loss drug), or both together change skin, joint, and fat tissue in adults with psoriatic arthritis who are overweight or obese.

  Recruiting NHS Greater Glasgow and Clyde · Birmingham, England and 3 other locations · NCT07443956

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.